Some experts warn that relying on the decisions of foreign drug regulators, such as the Food and Drug Administration, could water down Health Canada’s standards and open the door to reducing the number of scientific reviewers on staff.

Health Canada is planning to speed up reviews of some medications by piggybacking on the decisions of foreign regulators, including possibly the U.S. Food and Drug Administration, which has been in turmoil since Donald Trump returned to the White House a year ago.

Ottawa has not yet revealed which foreign drug authorities or which classes of drugs will be subject to the change, outlined in a draft ministerial order designed to quicken the pace of pharmaceutical approvals in Canada.


From The Globe and Mail via this RSS feed